Printed from Voxsanity (voxsanity.com.au) — NCT06419179 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, By Invitation
NCT06419179
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been newly diagnosed with advanced or metastatic small-cell lung cancer (either stage III that cannot be treated with curative radiation and chemotherapy combined, or stage IV).
- People who have a tumor tissue sample available — either a recent biopsy taken during routine care or a stored sample taken no more than 6 months before the screening process begins.
- People who are planned to receive, or are currently receiving, a standard first-line treatment combination of carboplatin or cisplatin, etoposide, and durvalumab — and where the pre-screening process begins no later than the start of the third treatment cycle.
- People who have chest and abdominal CT or MRI scan results available from within 42 days before starting that first-line treatment combination.
- People who have at least one area of disease that can be measured on scans, according to standard measurement guidelines (RECIST v1.1).
- People whose tumor sample has tested positive for a specific genetic marker called homologous recombination deficiency (HRD), confirmed through central laboratory testing as part of this trial's pre-screening process.
- People whose disease has not progressed (gotten worse on scans or symptoms) while on the initial treatment phase.
- People who have completed exactly 4 cycles (each 21 days long) of the initial treatment with carboplatin or cisplatin, etoposide, and durvalumab, finishing between 1 and 14 days before starting the study treatment — and who received durvalumab at least 3 times during those 4 cycles.
- People whose organ and bone marrow function meet the levels required by the trial (confirm with trial site for specific thresholds).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who received a different initial treatment combination than carboplatin or cisplatin, etoposide, and durvalumab (note: one cycle without durvalumab may be permitted — confirm with trial site).
- People whose cancer has shown signs of progression on scans or through symptoms.
- People who previously went through the pre-screening process for this trial and received a negative HRD test result.
- People who have brain or central nervous system (CNS) spread of their cancer that is causing symptoms and is not well controlled.
- People who have compression of the spinal cord, unless they have already received full treatment for it and their condition has been stable for at least 28 days.
- People who have a history of cancer spreading to the lining around the brain and spinal cord (leptomeningeal carcinomatosis).
- People who still have unresolved side effects rated at a moderate level or above (Grade 2 or higher) from previous cancer treatment — though certain exceptions may apply, including hair loss, a skin pigmentation condition called vitiligo, a stable thyroid condition managed with medication, nerve-related side effects (assessed individually), or certain permanent side effects not expected to be worsened by this trial's treatments (confirm with trial site for all exceptions).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
By Invitation
Phase
Phase 2
Sponsor
University of Cologne
Registry
ClinicalTrials.gov
Start date
9 October 2024
Est. completion
1 September 2026
Where this trial is recruiting
🇩🇪 Germany
Primary endpoints
Progression-free survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.